TB patients on second-line treatment experience a significant number of adverse effects. Some TB medicines result in adverse effects that, if not continuously monitored, can become serious and/or permanent and may hinder patient adherence to treatment. A number of other risk factors can also impact the safety of patients taking TB medicines, including drug interactions […]
Archive | Pharmaceutical SystemsRSS feed for this section
SIAPS, in partnership with the FDA, NTP, and LCP-NCPR, conducted a readiness assessment to determine the current information technology (IT) infrastructure, human resources, processes, and data management and quality control mechanisms available and to identify gaps in the current PV recording and reporting of patients in the seven Programmatic Management of Drug-Resistant TB (PMDT) treatment facilities implementing the 9MTR for multidrug-resistant (MDR)-TB study. The results of this assessment will provide inputs for developing the PViMS implementation plan.
An online system for monitoring and reporting cases of adverse drug reactions and lack of efficacy of medicines comprehensively addresses the need for improved access to quality, safe, and effective medicines. “The evaluation and analysis of PAIS system in Ukraine has brought out gaps and identified recommendations on operational PAIS system optimization and enhancing its […]
Key to the success of any health systems strengthening project is whether it effects broad, sustainable, institutional change. Sound strategic planning can grow a successful hospital pilot program into a nationwide health intervention that improves lives. The examples below show the SIAPS program’s work in bringing pharmaceutical systems strengthening interventions to scale. Technical Publication: Transforming Pharmaceutical […]
Technical Highlight: Strengthening Regulatory Systems in Democratic Republic of the Congo to Improve Access to Safe, Effective, and Quality Medicines
Chronic underfunding of the health sector coupled with long-term civil unrest in the Democratic Republic of the Congo (DRC) has contributed to insufficient regulatory capacity to effectively manage the registration and approval of new medicines in the country. In partnership with the USAID-funded SIAPS Program, the country’s Ministry of Health supported a number of broad interventions to strengthen DRC’s pharmaceutical regulatory system. SIAPS provides technical assistance to the three national control programs—malaria, HIV/AIDS, and tuberculosis—to improving access to quality medicines and other commodities and increase the potential for achieving desired health outcomes.
A new collection of technical briefs highlight strategic approaches, innovations, results and lessons learned in implementing systems-wide interventions to strengthen pharmaceutical systems and services in three countries: South Africa, Namibia and Ethiopia. Click on the thumbnails below to read the full technical briefs. Strengthening Namibia’s Pharmacy Sector and Workforce Strengthening the Leadership and Management of […]
By Tsion Issayas, Communications Manager for SIAPS Ethiopia. This post originally appeared on MSH’s website. Aster Amanuel Desalegn lives in Debre Markos, 190 miles from the Ethiopian capital of Addis Ababa. She is a 70-year-old mother of four and grandmother of two. Her granddaughters, Emuye, 6, and Blen, 8, live with her. On a trip back […]
By Liza Talukder, Communications Technical Advisor and Dr. Seikh Asiruddin, Senior Technical Advisor for SIAPS Bangladesh. This post originally appeared on MSH’s website. Tama, a resident of Parokhali village in the Khulna district of Bangladesh, was devastated when her 15-day-old daughter was diagnosed with pneumonia-related complications and needed treatment, including immediate oxygen support. Following instructions from the […]
Developing a CMS strategic plan can help align pharmaceutical supply chain objectives with overall public-sector health supply chain strategies. It can help ensure that health commodities are readily available to health facilities through an uninterrupted supply chain; minimize waste and losses; improve business and financial growth; and respond to changes in the supply chain, such as new technologies and emerging markets. In addition, advocating for and encouraging stakeholders to assess the medicine supply chain system can increase interest in generating additional technical, financial, and material resources for health care. Supply chain interventions can also contribute to improving rational medicine use and strengthening pharmaceutical regulation.
South Sudan’s health system is struggling to overcome a myriad of challenges, including poor pharmaceutical supply management practices, weak infrastructure, and inadequate skilled manpower. The outbreak of civil unrest in the nascent nation in December 2013 further exacerbated the already dire situation. South Sudan has one of the highest maternal mortality rates in the world, estimated at 789/100,000 live births. The country’s HIV prevalence rate increased from about 2% in 2000 to 2.6% in 2015 among adults, according to the South Sudan HIV/AIDS Commission and Ministry of Health. As of 2014, only 6% of 15 million people living with HIV were on antiretroviral therapy (ART).